Stay updated on TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial

Sign up to get notified when there's something new on the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The Taoyuan District entry was replaced with Taoyuan in the Taiwan location list (code 333), standardizing the city label without changing the site code.
    Difference
    0.0%
    Check dated 2026-05-07T18:42:50.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    Revision: v3.5.3 is now displayed on the page, replacing the previous Revision: v3.5.2. This reflects a small update to the page's release metadata rather than any substantive change to study content.
    Difference
    0.0%
    Check dated 2026-04-30T15:36:53.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The footer now shows Revision: v3.5.2, replacing the previous Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-16T10:37:31.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Added new study identifiers KEYNOTE-E10, MK-3475-E10, and jRCT2061220066; removed MK3475-C73 and updated the registry labeling.
    Difference
    0.1%
    Check dated 2026-03-25T20:27:48.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added, replacing v3.4.2 in the page's release notes.
    Difference
    0.0%
    Check dated 2026-03-11T14:25:55.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    Added detailed primary objectives (PFS/OS) and endpoint definitions (ORR, DoR, DCR, PFS, OS) along with TROP2 NMR assessment and IPD data-sharing information. Removed or altered several earlier endpoint definitions, time frames, and explicit eligibility criteria.
    Difference
    0.7%
    Check dated 2026-02-24T09:21:13.000Z thumbnail image

Stay in the know with updates to TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page.